Creative Enzymes, a global enzyme technology service provider, announced the launch of an AI-integrated biocatalysis platform designed to address the growing gap between the identification of application opportunities and the availability of suitable enzymes. The platform merges computational enzyme engineering with hands-on process development to deliver what the company calls AI-Driven Biocatalysis Solutions that are predictable in silico and practical at industrial scale.
Biocatalysis is an established manufacturing process, but traditional development approaches struggle to meet the speed requirements of iterative product development. AI brings critical value on three fronts: predicting enzyme candidates best suited for a given biocatalytic reaction; designing enzymes constrained by process parameters rather than biological factors; and leveraging key molecular features to anticipate process performance in advance. These capabilities reduce the need to experiment with numerous biocatalyst variants, saving on R&D costs and lowering the risk of process failure by identifying suitable biocatalysts earlier in development.
The platform's capabilities are delivered through three specialized service modules. The AI-Driven Biocatalysis Solutions module offers an end-to-end workflow encompassing target reaction analysis, computational screening, process optimization, and scale-up evaluation. For moderately complex targets, this structured approach reduces the design-build-test-learn cycle from 12–24 months to just 8–12 months. The AI-Driven Industrial Biocatalysis module focuses on closing the divide between lab-scale performance and commercial production, addressing substrate concentration optimization, cofactor regeneration, immobilization, and integration of process analytical technology. The AI-Driven Green Biocatalysis module provides sustainability-focused solutions that minimize organic solvent use, reduce heating and cooling requirements, and cut waste generation through enzymatic selectivity.
The platform's capabilities have been demonstrated through a recent case study in transaminase engineering. Researchers developed a 6D protein engineering framework that combines interaction energy, solvent effects, and 1.39 million structural fragments to predict beneficial mutations. Five transaminase variants selected by AI—each with nine mutations—exhibited high solubility and catalytic stability at 7-liter fermentation scale. The engineered enzymes convert prochiral ketones to sitagliptin, delivering enantiomeric purity exceeding 99% and conversion rates of up to 89% during scale-up production.
Pharmaceuticals are currently the primary sector benefiting from AI biocatalysis, particularly in asymmetric synthesis of chiral intermediates and replacing hazardous reagents. Agrochemicals and food industries are also adopting the technology to fine-tune toxicology profiles and deliver cleaner labels through enzymatic modification. Fine chemicals and personal care sectors are beginning to explore high-value conversions and milder, more sustainable processes.
By providing a systematic approach that merges computational predictions with empirical evidence, Creative Enzymes' platform aims to accelerate the development of practical, economically sound enzyme catalysts for industrial applications.
